Thailand once bet big on cannabis. Now, with public opinion turning and an election ahead, that gamble may backfire.@patpichatan explains: https://t.co/3t0kraAonM https://t.co/RjwhKev3M2 ...

Industry Overview - The cannabis industry is undergoing significant changes with new laws and regulations that support its development [1][2] - Investors are focusing on companies that demonstrate strong performance or are working towards substantial goals, which can lead to profitability [1] Investment Opportunities - In 2026, there is anticipation for a new marijuana stock run, with potential breakout opportunities for various cannabis stocks [2][3] - It is crucial for investors to prepare for the volatility inherent in the cannabis sector [2] Key Companies to Watch - **Tilray Brands, Inc.**: Engages in the research, cultivation, processing, and distribution of medical cannabis products across multiple regions including Canada, the US, and Europe [4] - Recently appointed Romano Beverage to enhance distribution in Illinois, indicating a strategic move to accelerate growth [5][6] - **Cronos Group Inc.**: Focuses on the cultivation, production, distribution, and marketing of cannabis products internationally [8] - Launched its Lord Jones® premium cannabis brand in Israel, highlighting its strategy to penetrate key markets [9][10] - **SNDL Inc.**: Involved in the production and distribution of cannabis products for the adult-use market in Canada [10] - Announced a share repurchase program authorizing the repurchase of up to C$100 million of its outstanding common shares, indicating confidence in its stock value [12][13]

CHICAGO--(BUSINESS WIRE)--Turn, the AI-native workforce screening and compliance infrastructure company, today announced that it has been selected by Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF), a leading global cannabis operator, to support background screening across Curaleaf's workforce. "Turn's technology-driven approach supports our operational and compliance requirements while enabling a consistent hiring experience across the organization,†said Camilo Lyon, Chief Investment Officer at Curaleaf ...

Core Insights - Aurora Cannabis reported a consolidated adjusted gross margin of 62%, an increase of 100 basis points year over year, with adjusted gross profit rising 6% to CAD 55.6 million [1] - The company’s total net revenue reached CAD 94.2 million, with medical cannabis contributing 81% of this revenue, up from 77% the previous year [2] - CEO Miguel Martin highlighted a 7% year-over-year increase in net revenue, driven by a 12% rise in medical cannabis revenue to CAD 76.2 million, including a 17% growth in international markets [3][4] Financial Performance - For fiscal Q3 2026, net revenue increased 7% year over year to CAD 94.2 million, with adjusted EBITDA at CAD 18.5 million, down from CAD 19.4 million in the prior year [7] - The company generated positive free cash flow of CAD 15.5 million, a decrease from CAD 27.4 million in the previous year, ending the quarter with CAD 154 million in cash and no cannabis-related debt [8] - Adjusted net income was CAD 7.2 million compared to CAD 7.4 million a year earlier [7] Strategic Initiatives - Aurora is exiting select low-margin Canadian consumer markets and plans to divest its controlling stake in Bevo, a plant propagation business, to focus on higher-margin global medical cannabis [6][9] - The company filed a prospectus supplement for a new at-the-market (ATM) equity program to raise up to $100 million for strategic purposes, including increased cultivation capacity and potential M&A [14] - Management anticipates one-time costs in Q4 due to these strategic changes but expects improved adjusted SG&A and margins thereafter [10] Market Expansion - Aurora projects FY2026 global medical cannabis revenue between CAD 269 million and CAD 281 million, representing a growth of 10% to 15% [5][20] - The company is focusing on expanding its presence in Germany, which is described as Europe's largest medical cannabis market, and is doubling production at its German manufacturing site [15][16] - In Poland, Aurora gained market share and held the number one position in 2025, successfully navigating regulatory shifts [18] Future Outlook - Management expects annual consolidated adjusted EBITDA to rise to a range of CAD 52 million to CAD 57 million, indicating 5% to 10% annual growth [21] - The company aims to leverage its regulatory capabilities and manufacturing efficiencies to capitalize on the evolving global medical cannabis market [22]

Core Insights - The company is a leading player in the global medical cannabis market, with a strong focus on international markets and compliance with stringent regulatory standards [1][3][23] - The company reported a 7% increase in net revenue, driven by a 12% growth in global medical cannabis revenue, with international sales growing by 17% [3][17] - The company is strategically exiting lower-margin consumer cannabis markets in Canada to focus on higher-margin medical cannabis operations [4][5][14] Financial Performance - Adjusted gross margin increased by 100 basis points to 62%, with medical cannabis margins at 69% due to growth in higher-margin international markets [2][16] - Adjusted EBITDA was reported at $18.5 million, with adjusted net income of $7.2 million and positive free cash flow of $15.5 million [2][17] - The company ended the quarter with $154 million in cash and no cannabis-related debt, maintaining a strong balance sheet [2][20] Market Strategy - The company is reallocating resources from the Canadian consumer cannabis segment to enhance its global medical cannabis business, which is expected to drive profitability [4][5][14] - The company plans to divest its lower-margin plant propagation operations to focus on higher-margin segments [5][32] - The company is expanding its product offerings in key international markets, including Germany and Australia, to capture growth opportunities [6][10][12] International Market Insights - Germany is highlighted as a significant market, with imports expected to double in 2025, driving the company's international revenue growth [7][9] - The Australian market is seen as a $1 billion opportunity, with efforts to shift sales towards premium products to improve margins [9][10] - The company is actively exploring new international markets, including Switzerland, Austria, and Turkey, to expand its footprint [50][57] Future Outlook - Annual global medical cannabis net revenue is projected to increase to between $269 million and $281 million, driven by 10% to 15% growth in the global medical cannabis segment [21][20] - Consolidated adjusted EBITDA is anticipated to grow by 5% to 10% year-over-year, reflecting the company's focus on high-margin medical cannabis operations [21][20] - The company is committed to maintaining its leadership position in the global medical cannabis market while exploring strategic opportunities for growth [23][46]

Financial Data and Key Metrics Changes - Net revenue increased by 7% to CAD 94.2 million, driven by a record 12% growth in global medical cannabis revenue, including a 17% increase internationally [4][16] - Adjusted gross margin rose by 100 basis points to 62%, with adjusted gross profit reaching CAD 55.6 million, a 6% increase [16] - Adjusted EBITDA was CAD 18.5 million, and adjusted net income was CAD 7.2 million, with positive free cash flow of CAD 15.5 million [5][17] - The company ended the quarter with CAD 154 million in cash and no cannabis business-related debt [5][17] Business Line Data and Key Metrics Changes - Medical cannabis net revenue rose by 12% to CAD 76.2 million, comprising 81% of total net revenue, compared to 77% in the prior year [17] - Consumer cannabis net revenue decreased by 48% to CAD 5.2 million, reflecting the strategic shift to focus on higher-margin global medical cannabis [18] - Bevo's plant propagation net revenue increased by 27% to CAD 11.3 million, but adjusted gross margin fell to 16% from 40% due to increased costs [19] Market Data and Key Metrics Changes - The German market, as the largest individual medical cannabis market in Europe, was a primary driver of double-digit growth in international revenue [8][9] - Australia is the largest international medical cannabis market for the company, with a potential AUD 1 billion opportunity, where the company holds the number two market share [11] - In Poland, the company maintained its number one position in market share, benefiting from increased annual import limits [13] Company Strategy and Development Direction - The company is focusing on exiting select markets within the lower Canadian consumer cannabis segment to prioritize higher-margin global medical cannabis [7] - A divestiture of the lower-margin plant propagation operations is planned to allocate capital more effectively and improve profitability [7] - The company aims to enhance its leadership position in global medical cannabis by solidifying its market presence in Canada, Europe, Australia, and New Zealand, while exploring new markets [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's competitive position in the global medical cannabis market, projecting significant growth opportunities [4][23] - The company anticipates annual global medical cannabis net revenue to increase to between CAD 269 million and CAD 281 million, driven by 10%-15% growth in the segment [21][22] - Management acknowledged potential headwinds in some markets but remains optimistic about the overall growth trajectory [55] Other Important Information - The company filed a prospectus supplement to establish a new At-the-Market equity program, allowing it to issue and sell up to $100 million of common shares [8] - The company is committed to maintaining high-quality standards in its products, with 90% of annual manufacturing capacity produced in GMP-certified facilities [6] Q&A Session Summary Question: Follow-up on the select market exit in Canada - Management indicated that exiting these markets will be beneficial to overall financial results and will allow for resource reallocation to international markets [25][27] Question: Impact of premiumization strategy in Australia - Management stated that the shift towards premium products is not disruptive and is expected to enhance margins [29][30] Question: Strategic decision to exit plant propagation - Management emphasized the focus on global medical cannabis as the most profitable area and the rationale behind divesting the plant propagation business [37][39] Question: Contribution of plant propagation to EBITDA - Management noted that the financial results of the plant propagation business will be treated as discontinued operations going forward [40] Question: Navigating regulatory changes in Poland - Management highlighted the company's strong relationships with regulators and its ability to adapt to changes in the regulatory environment [42][43] Question: Clarity on global medical cannabis revenue guidance - Management clarified that the guidance reflects total revenue, including the impact of the divestiture of Bevo [48][49] Question: Reasons for higher wholesale gross margins compared to consumer cannabis - Management explained that the consumer cannabis market is tight, leading to lower margins, while wholesale products are less available globally due to regulatory requirements [56][57] Question: Potential assets for M&A - Management expressed interest in cultivation capacity and other aspects of global medical cannabis, remaining opportunistic with the funds raised [61][62] Question: Supply chain and cultivation capacity - Management confirmed that nearly all products sold are produced in-house, with a focus on maintaining high-quality GMP flower [75][78]

Core Viewpoint - Cannara Biotech Inc. has completed a strategic non-brokered private placement with Phoenician Capital LLC, raising C$6,300,000 through the issuance of 3,000,000 common shares at a price of C$2.10 per share, which is a 16% premium over the closing price prior to the announcement [1][2]. Group 1: Private Placement Details - The proceeds from the private placement will be utilized for working capital and strategic investments, including capital investments in the Valleyfield Facility and operational expansion [2]. - The common shares issued are subject to a statutory hold period of four months and one day, in accordance with Canadian securities laws [3]. Group 2: Management Commentary - The CEO of Cannara, Zohar Krivorot, stated that the investment aligns with the company's expansion strategy and reflects confidence in its operational model [3]. - John Khabbaz, from Phoenician, expressed support for Cannara's focus on operational discipline and long-term value creation [3]. Group 3: Secondary Share Sale - Zohar Krivorot has agreed to sell 333,333 common shares to Phoenician at the same price of C$2.10 per share, which is intended to offset personal tax losses [5]. - Following the secondary share sale, Krivorot's ownership will decrease from approximately 26.99% to 25.83% of the issued and outstanding common shares [6]. Group 4: Company Overview - Cannara Biotech Inc. is a vertically integrated producer of premium-grade cannabis products, operating two facilities in Québec with a total area of over 1,600,000 sq. ft. and a potential annual cultivation output of 100,000 kg [16].

Core Viewpoint - Aurora Cannabis Inc. has announced the establishment of a new at-the-market offering program allowing the issuance and sale of up to U.S.$100 million of common shares to the public at the company's discretion [1]. Group 1: Offering Details - The net proceeds from the offering will be used for strategic and accretive purposes, including increased cultivation capacity and mergers and acquisitions (M&A) [2]. - Common shares will be sold through "at-the-market distributions" on the NASDAQ or other U.S. marketplaces at the prevailing market price, with no sales occurring in Canada [3]. - The sales will be conducted under a sales agreement with TD Securities (USA) LLC dated February 4, 2026 [4]. Group 2: Regulatory Filings - A prospectus supplement has been filed with securities commissions in Canada (excluding Quebec) and with the U.S. Securities and Exchange Commission (SEC) as part of the company's registration statement under the U.S./Canada Multijurisdictional Disclosure System [5]. Group 3: Company Overview - Aurora Cannabis is a global leader in medical cannabis, focusing on improving lives through scientific expertise and a commitment to patient care, serving both medical and consumer markets across multiple regions [7]. - The company has a portfolio of trusted brands and holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants [7].

Core Viewpoint - Green Thumb Industries Inc. is set to release its fourth quarter and full year 2025 financial results on February 25, 2026, after market close [1] Company Overview - Green Thumb Industries Inc. is a leading national cannabis consumer packaged goods company and retailer based in Chicago, Illinois [2] - The company manufactures and distributes a variety of licensed, branded cannabis products, including RYTHM, Dogwalkers, incredibles, Beboe, &Shine, Doctor Solomon's, and Good Green [2] - Green Thumb operates RISE Dispensaries, a rapidly growing national retail chain, serving millions of patients and customers annually [2] - Established in 2014, Green Thumb has manufacturing facilities and retail stores across 14 U.S. markets, employing approximately 4,800 people [2]

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025. 11 1 "Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market. We achieved record quarterly net revenue of $76.2 million in our globa ...